Trial
NCT01918306
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Vanderbilt-Ingram Cancer Center
Collaborators
National Cancer Institute (NCI); Genentech, Inc.
Condition
Estrogen Receptor Negative Breast Cancer
Intervention
cisplatin
Why stopped
company stopped production of study drug due to excessive toxicities, lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-27